

1 **Detection of anti-premembrane antibody as a specific marker of four**
2 **flavivirus serocomplexes and its application to serosurveillance in endemic**
3 **regions**

4 Guan-Hua Chen^{a†}, Yu-Ching Dai^{a†}, Szu-Chia Hsieh^a, Jih-Jin Tsai^{b,c,d}, Ava Kristy Sy^e, Mario Jiz^f,
5 Celia Pedrosa^g, Carlos Brites^g, Eduardo Martins Netto^g, Phyllis J. Kanki^h, Danielle R. D.

6 Saundersⁱ, Dana L. Vanlandingham^j, Stephen Higgs^j, Yan-Jang S. Huang^j, Wei-Kung Wang^{a*}

7 ^aDepartment of Tropical Medicine, Medical Microbiology and Pharmacology, John A. Burns

8 School of Medicine, University of Hawaii at Manoa, Honolulu, Hawaii, USA; ^bTropical Medicine

9 Center, ^cDivision of Infectious Diseases, Department of Internal Medicine, Kaohsiung Medical

10 University Hospital, ^dSchool of Medicine, College of Medicine, Kaohsiung Medical University,

11 Kaohsiung, Taiwan; ^eNational Reference Laboratory for Dengue and Other Arbovirus, Virology

12 Department, and ^fImmunology Department, Research Institute for Tropical Medicine, Muntinlupa

13 City, Philippines; ^gLAPI-Laboratório de Pesquisa em Infectologia-School of Medicine, Federal

14 University of Bahia, Salvador, Brazil; ^hDepartment of Immunology and Infectious Diseases,

15 Harvard T.H. Chan School of Public Health, Boston, Massachusetts, USA; ⁱDepartment of

16 Biology, United States Air Force Academy, USA; ^jBiosecurity Research Institute and Department

17 of Diagnostic Medicine/Pathobiology, College of Veterinary Medicine, Kansas State University,

18 Kansas, USA

19 [†]These authors contribute equally to this work.

20 Contact: Wei-Kung Wang, wangwk@hawaii.edu, Department of Tropical Medicine, Medical

21 Microbiology and Pharmacology, John A. Burns School of Medicine, University of Hawaii at

22 Manoa, Honolulu, HI 96813, USA

23 Keywords: Yellow fever virus, flavivirus, antibody, premembrane protein, serosurveillance

25 **ABSTRACT**

26 In the past few decades, several emerging/re-emerging mosquito-borne flaviviruses have
27 resulted in disease outbreaks of public health concern in the tropics and subtropics. Due to cross-
28 reactivities of antibodies recognizing the envelope protein of different flaviviruses,
29 serosurveillance remains a challenge. Previously we reported that anti-premembrane (prM)
30 antibody can discriminate between three flavivirus infections by Western blot analysis. In this
31 study, we aimed to develop a serological assay that can discriminate infection or exposure with
32 flaviviruses from four serocomplexes, including dengue (DENV), Zika (ZIKV), West Nile
33 (WNV) and yellow fever (YFV) viruses, and explore its application for serosurveillance in
34 flavivirus-endemic countries. We employed Western blot analysis including antigens of six
35 flaviviruses (DENV1, 2 and 4, WNV, ZIKV and YFV) from four serocomplexes. We tested
36 serum samples from YF-17D vaccinees, and from DENV, ZIKV and WNV panels that had been
37 confirmed by RT-PCR or by neutralization assays. The overall sensitivity/specificity of anti-prM
38 antibodies for DENV, ZIKV, WNV, and YFV infections/exposure were 91.7%/96.4%,
39 91.7%/99.2%, 88.9%/98.3%, and 91.3%/92.5%, respectively. When testing 48 samples from
40 Brazil, we identified multiple flavivirus infections/exposure including DENV and ZIKV, DENV
41 and YFV, and DENV, ZIKV and YFV. When testing 50 samples from the Philippines, we
42 detected DENV, ZIKV, and DENV and ZIKV infections with a ZIKV seroprevalence rate of
43 10%, which was consistent with reports of low-level circulation of ZIKV in Asia. Together,
44 these findings suggest that anti-prM antibody is a flavivirus serocomplex-specific marker and
45 can be employed to delineate four flavivirus infections/exposure in regions where multiple
46 flaviviruses co-circulate.

47 **Introduction**

48 In the genus *Flavivirus* of the family *Flaviviridae*, there are several mosquito-borne viruses
49 causing significant diseases in humans; including the four serotypes of dengue virus (DENV) in
50 the DENV serocomplex, West Nile virus (WNV) and Japanese encephalitis virus (JEV) in the
51 JEV serocomplex, Zika virus (ZIKV), and yellow fever virus (YFV) as a single member [1].

52 The four serotypes of DENV (DENV1-DENV4) continue to be a global public health threat in
53 tropical and subtropical regions [2-4]. It has been estimated that approximately 390 million
54 DENV infections occur annually worldwide [2-4]. Most DENV infections are inapparent or
55 subclinical with about 25% leading to clinical disease including dengue, dengue with warning
56 signs, and severe dengue [2-4]. Of the DENV vaccine candidates that have completed different
57 phases of clinical trials, Dengvaxia, a chimeric yellow fever-dengue tetravalent vaccine, was the
58 first DENV vaccine licensed [5]. As DENV-seronegative children receiving Dengvaxia were
59 reported to have a higher risk for hospitalization and severe dengue during subsequent DENV
60 infection, Dengvaxia was recommended for DENV-seropositive individuals aged 9–45 years [5-
61 7]. Pre-vaccination screening strategies using assays with high sensitivity and specificity have
62 been proposed, highlighting the need for reliable serological tests to determine DENV serostatus
63 in flavivirus-endemic regions [8].

64 Three additional flaviviruses, YFV, WNV, and ZIKV were also included in this research. In
65 sub-Saharan Africa and tropical America, YFV is endemic with an estimate of 200,000 severe
66 cases and up to 60,000 deaths per year [9,10]. The recent outbreaks in Angola and the
67 Democratic Republic of the Congo, followed by the outbreaks in Brazil and Nigeria, suggest that
68 YFV has expanded to new areas to affect large populations in South America and Africa [9,10].
69 First isolated in Uganda in 1937, WNV caused human cases and outbreaks in Africa and Europe;

70 since 1999 WNV has spread throughout the continental U.S. and to Canada and Mexico [1,11].
71 The reports of increased incidence in the geographic distribution of WNV and travel-related
72 WNV cases posed new challenge of serosurveillance for flaviviruses [11,12]. ZIKV, first
73 isolated in Uganda in 1947, was associated with relatively few human cases until the outbreaks
74 on Yap Island in 2007 and French Polynesia in 2013–2014. The subsequent explosive spread in
75 the Americas since 2015 has resulted in ~800,000 suspected or confirmed cases [13,14]. The
76 association of ZIKV with microcephaly and other birth defects, known as congenital Zika
77 syndrome (CZS), has raised global public health concern [13-15]. Despite a decline in ZIKV
78 transmission since late 2017, the specter of its re-emergence and CZS in the endemic regions
79 remains.

80 Knowing the seroprevalence rates of flaviviruses is critical to our understanding of the
81 epidemiology and transmission dynamics of flaviviruses and critical for the development of
82 intervention strategies. In addition, information about DENV serostatus can be used to evaluate
83 DENV vaccine efficacy and determine if an individual would benefit from Dengvaxia and/or
84 other vaccine candidates. Due to the presence of mosquito vectors in the regions, there is
85 considerable geographic overlap in the distribution of different flaviviruses, such as DENV, JEV
86 and ZIKV in Southeast Asia; DENV, YFV and ZIKV in South America; and DENV, YFV, WNV
87 and ZIKV in sub-Saharan Africa. Our knowledge about the effects of prior immunity to one
88 flavivirus on disease outcome of infection with another flavivirus in humans was primarily based
89 on cohort studies. It has been reported that preexisting JEV neutralizing antibodies increased
90 symptomatic DENV infection in Thailand [16]. Since the ZIKV outbreak during 2015–2017,
91 two studies reported that prior DENV infection was associated with reduced risk of symptomatic
92 ZIKV infection [17,18]. Another study showed that one prior ZIKV infection or one prior DENV

93 followed by one ZIKV infection increased the risk of subsequent symptomatic DENV2 infection
94 and severe disease, whereas a prior ZIKV with two or more DENV infections had a protective
95 effect [19], underscoring the importance of reliable serological tests that can discriminate DENV,
96 ZIKV and/or other flavivirus infections to improve our understanding of the complex
97 interactions between DENV, ZIKV and/or other flaviviruses in endemic regions.

98 Present on the surface of flavivirus particles, the envelop (E) protein is the major target of
99 neutralizing antibodies and vaccine development [1,20]. The ectodomain of the E protein
100 contains 3 domains; the fusion loop (FL) is located at the tip of domain II and contains several
101 highly conserved residues [1,20]. The premembrane (prM) protein, a glycoprotein of ~19 kDa, is
102 cleaved by furin or furin-like protease to precursor (pr) and membrane (M) proteins during
103 maturation in the *trans*-Golgi [1,20]. Several serological tests have been developed based on the
104 E protein including recombinant E protein, inactivated virions, or virus-like particles (VLPs)
105 [20-23]. Due to cross-reactivity of anti-E antibodies to different flaviviruses, E protein-based
106 serological tests cannot discriminate different flavivirus infections [20,23-27]. Nonstructural
107 protein 1 (NS1)-based serological tests including enzyme-linked immunosorbent assay (ELISA),
108 blockade of binding ELISA, and microsphere immunoassay have shown improved specificity
109 [28-32]. However, the reduced durability of anti-NS1 antibodies could be a challenge for
110 seroprevalence studies.

111 The plaque reduction neutralization test (PRNT) is considered the gold standard serological
112 test and has been employed to confirm different flavivirus infections in serosurveillance and
113 seroprevalence studies [1,23]. For individuals experiencing a single flavivirus infection, it
114 identifies monotypic neutralizing antibodies against a single flavivirus, such as neutralizing
115 antibody against one DENV serotype or ZIKV in individuals with primary DENV (pDENV) or

116 primary ZIKV (pZIKV) infection, respectively [23,33-35]. For individuals experiencing multiple
117 flavivirus infections, it reveals multitypic neutralizing antibodies against multiple flaviviruses,
118 such as two or more DENV serotypes and/or other flaviviruses in individuals with secondary
119 DENV (sDENV) infection [23,33-35]. Therefore, multitypic neutralizing antibodies were
120 interpreted as unspecified flavivirus infections and cannot discriminate between the flaviviruses
121 experienced in the past such as sDENV infection versus previous DENV and ZIKV
122 (DENV+ZIKV) infections [23].

123 Previously, we employed Western blot analysis using an antigen panel of six flavivirus-
124 infected cell lysates (DENV1-4, WNV and ZIKV) from three serocomplexes to test different
125 panels with known flavivirus infections and reported that anti-prM antibodies can discriminate
126 between DENV, ZIKV and WNV infections [36]. Whether or not this assay can be extended to
127 include other flaviviruses such as YFV and applied to serosurveillance in flavivirus-endemic
128 regions remains unanswered. In this study, we aimed to develop a serological test that can
129 discriminate infection of flaviviruses from four serocomplexes including DENV, ZIKV, WNV
130 and YFV, and examine samples collected from serosurveillance in the Philippines and Brazil.
131 The underlying hypothesis was that detection of anti-prM antibody can discriminate infections
132 caused by four flavivirus serocomplexes. We found anti-prM antibody is a specific marker for
133 four flavivirus serocomplexes.

134 **Materials and methods**

135 ***Human samples***

136 This study was approved by the Institutional Review Boards (IRBs) of the University of Hawaii
137 (CHS#17568, 2022-00201, 2021-00947), the Kaohsiung Medical University Hospital, Taiwan
138 (KMUH-IRB-960195, KMUH-IRB-E[I]-20170185), and the Research Institute for Tropical
139 Medicine (RITM), Philippines (2019-042). The numbers, sampling time, sources and
140 confirmation methods of different panels of serum or plasma samples with known flavivirus
141 infections or vaccination are summarized in Table S1. Samples from reverse transcription-
142 polymerase chain reaction (RT-PCR)-confirmed Zika cases including previously DENV-naïve
143 (n=18) or DENV-exposed (n=13), designated as pZIKV or DENV+ZIKV panels respectively,
144 were collected between July and March 2017 from the Pediatric Dengue Cohort Study and the
145 Pediatric Dengue Hospital-based Study in Managua, Nicaragua [37,38]. The studies were
146 approved by the IRBs of the University of California, Berkeley, and the Nicaraguan Ministry of
147 Health. Samples from a ZIKV study in Salvador, an epicenter of ZIKV outbreak in Brazil, were
148 confirmed by microneutralization tests (to ZIKV and DENV) as pZIKV (n=5), DENV+ZIKV
149 (n=12), pDENV (n=4), and sDENV (n=21) panels as described previously [39]. The study was
150 approved by Approved the Comitê de Ética em Pesquisa da Maternidade Climério de
151 Oliveira/UFBA, Brazil (CAAE: 25336819.3.0000.5543/4.691.233, 2019). Samples (n=18) from
152 blood donors, who tested positive for WNV transcription-mediated amplification (TMA), IgM
153 and IgG antibodies, were designated as the WNV infection panel, were provided by the
154 American Red Cross at Gaithersburg, Maryland [40]. Samples from a DENV seroprevalence
155 study in Kaohsiung, Taiwan were confirmed by a microneutralization test (to DENV) as pDENV
156 (n=17), sDENV (n=29) or DENV-naive (n=29) [41,42]; the sampling time was available based

157 on questionnaires from study participants. Samples of YF-17D vaccinees were from the US
158 (n=10) and Brazil (n=9) based on history of YF-17D vaccination [43]; samples from non-human
159 primates (NHP) receiving YF-17D vaccine (n=4) were from the BEI Resources (NIAID, NIH).
160 Additionally, samples from 50 participants (aged 2 to 56 years) collected between January 2018
161 and May 2019 from a fever surveillance program at the RITM, Philippines were included as a
162 test panel [43]. These were non-Dengvaxia recipients and presented with symptoms suspected of
163 dengue; blood samples were negative by DENV RT-PCR or DENV IgM-capture ELISA.

164 Another panel of samples (n=48) of suspected ZIKV cases (aged 15–70 years) collected between
165 2015 and 2016 from the ZIKV study in Salvador, Brazil was included as a second test panel [31].

166 ***Western blot analysis***

167 Uninfected (mock) Vero cells and Vero cells infected with DENV1 (Hawaii strain), DENV2
168 (NGC strain), DENV4 (H241 strain), ZIKV (PRVABC59 strain), WNV (NY99 strain) or YFV
169 (17D vaccine strain) were lysed with NP-40 lysis buffer (1% NP-40, 50 mM Tris pH 8.0, 150
170 mM NaCl, 2 mM EDTA, and 1 mM Na₃VO₄) when 50% of cells were found to have cytopathic
171 effects. The cell lysates were loaded into two half-gels (seven wells each) and subjected to SDS-
172 12% polyacrylamide gel electrophoresis under non-reducing condition (2% SDS, 0.5 M Tris pH
173 6.8, 20 % glycerol, 0.001 % bromophenol blue, final) [24,36], followed by transfer to
174 nitrocellulose membrane (Trans-Blot Turbo RTA Midi Transfer Kit, BioRad), hybridization with
175 human serum/plasma samples (1:200 dilution) or mouse monoclonal antibody (mAb) and
176 secondary antibody (IRDye® 800CW-conjugated goat anti-human IgG at 1:10000). The signals
177 were detected by Li Cor Odyssey classic (LiCor Biosciences) and analyzed by Image Studio
178 software with both short and long exposures [36,42]. Each gel was read independently by two
179 researchers with the results summarized in Supplementary Table 2. To test the stability of the

180 assay, the half-membranes after blocking step were stored in the -20°C freezer until use for
181 hybridization to serum/plasma.

182 ***Expression of YF-17D prM/E proteins***

183 293T cells (1×10^5 cells) were transfected with 10 µg of a plasmid expressing the prM/E proteins
184 of YF-17D. At 48 h, cells were washed with 1X PBS and treated with 1% NP40 lysis buffer,
185 followed by centrifugation at $20,000 \times g$ at 4°C for 30 min to obtain cell lysates for Western blot
186 analysis probed with human dengue-immune serum as described above [24,36].

187 ***DENV FL-VLP IgG ELISA***

188 IgG ELISA using DENV1 FL-mutated VLPs was described previously [44]. Briefly, DENV1
189 FL-mutated VLPs (containing W101A and F108A mutations) were coated onto 96-well plates at
190 4°C overnight, followed by blocking (StartingBlock blocking buffer, Thermo Scientific,
191 Waltham, MA) at room temperature for 1 h, incubation with primary antibody (serum or plasma
192 at 1:400 dilution) at 37°C for 2 h, wash with washing buffer (0.5% Tween-20 in 1X PBS) 4
193 times, incubation with secondary antibody (anti-human IgG conjugated with horseradish
194 peroxidase [HRP] at 1:10,000 dilution, Jackson Immune Research Laboratory, West Grove, PA)
195 at 37°C for 1 h, and wash with washing buffer 6 times [40,44]. After incubation with
196 tetramethylbenzidine substrate (Thermo Scientific, Waltham, MA) at room temperature for 15
197 min and stop solution, the OD at 450 nm was read with a reference wavelength of 630 nm. Each
198 ELISA plate contained two positive controls (OD higher than 1; two confirmed-DENV samples),
199 four negative controls (DENV-naïve sera or plasma), and test samples (all in duplicate). For
200 comparison between plates, the relative OD (rOD) values were calculated by the OD values
201 divided by the mean OD value of one positive control (OD close to 1) in the same plate. The
202 cutoff rOD was defined by the mean rOD value of negatives plus 12 standard deviations, which

203 gave a confidence level of 99.9% from 4 negatives [45]. Each ELISA was performed in
204 duplicate.

205 ***Microneutralization test***

206 Microneutralization tests were performed as described previously [39,42]. Briefly, two-fold
207 serial dilutions of serum were mixed with 50 focus-forming units of DENV1 (Hawaii), DENV2
208 (NGC), DENV3 (CH53489), DENV4 (H241), ZIKV (PRVABC59), or YFV (YF-17D) at 37°C
209 for 1 h; the mixtures were added to each well of 96-well plate which was pre-seeded with Vero
210 cells (3×10^4 cells per well) one day prior to infection. This was followed by incubation at 37°C
211 for 48-70 h, removal of medium, fixation [39,42], mouse mAb 4G2 and secondary antibodies
212 (IRDye® 800CW-conjugated goat anti-mouse IgG and DRAQ5™ fluorescent probe at 1:10000).
213 The signals (800 nm/700 nm fluorescence) were detected using a LiCor Odyssey imager (LiCor
214 Biosciences) and analyzed by Image Studio to determine percent neutralization at different
215 concentrations and 90% neutralization (NT₉₀) titers [39,42].

216 ***Statistical analysis***

217 The sensitivity, specificity and 95% confidence intervals (CI) were calculated by Excel. The
218 two-tailed Fisher's exact test and two-tailed Mann-Whitney test were used to compare
219 categorical and quantitative variables, respectively, between two groups (GraphPad Prism 6).
220 The positive, negative and overall agreements and kappa assessment were calculated by the
221 SPSS 20.

222 **Results**

223 ***Antibody response following YF-17D vaccination***

224 The antigen panel in Western blot analysis included lysates derived from Vero cells infected with
225 six flaviviruses (DENV1, 2 and 4, WNV, ZIKV and YF-17D vaccine strain) from four
226 serocomplexes. The control panels with known flavivirus infections or vaccination included
227 serum or plasma samples from YF-17D vaccinees (YF-17D panel), RT-PCR-confirmed ZIKV
228 cases (pZIKV and DENV+ZIKV panels), TMA-confirmed WNV infection (WNV panel), and
229 neutralization-confirmed DENV infection or DENV-naïve participants (pDENV, sDENV and
230 DENV-naïve panels) from a DENV seroprevalence study (Table S1). We first examined antibody
231 response in two vaccinees ~3 months following YF-17D vaccination by Western blot analysis.
232 Each lane contained individual viral proteins presumably in equal molar ratio except for those
233 structural proteins released with virions; a previously described flavivirus group-reactive mouse
234 mAb FL0232, which recognized E proteins (DENV1-4, ZIKV, WNV and YFV) equally well, was
235 used to verify comparable amounts of loaded antigens (Figure 1(C)) [23,36]. DENV3-infected
236 cell lysate was not included due to high amino acid homology between DENV3 and DENV1
237 (compared with DENV2 or DENV4) and the convenience of loading seven lanes in a half
238 membrane. As shown in Figure 1(A), anti-E antibodies cross-reactive to all six flaviviruses tested,
239 and anti-NS1 and anti-prM antibodies recognizing YFV only were observed. A similar trend was
240 observed in 17 other samples, although some recognized YFV E protein only (Table S2). Notably,
241 the YFV prM protein migrated at a slower rate than the prM proteins of other flaviviruses
242 (DENV1, 2 and 4, WNV and ZIKV) tested, corresponding to the size of a 23 kDa protein; this
243 was confirmed by the size of prM protein expressed by a YF-17D prM/E plasmid (Figure 1(B)).
244 We next examined samples from three NHPs receiving YF-17D vaccine (1 to 18 months, pooled

245 sera); anti-E antibodies recognizing YFV and/or other five flaviviruses tested together with anti-
246 NS1 and anti-prM antibodies recognizing YFV only were observed (Figure 1(D)). As a
247 comparison, no protein band corresponding to E, NS1 or prM protein was recognized by a
248 DENV-naive sample (Figure 1(E), Table S2). Different viral protein bands recognized by samples
249 from 19 YF-17D vaccinees and four NHPs receiving YF-17D vaccine are summarized in Table 1.

250 ***Anti-prM antibodies can discriminate four flavivirus infections or exposure***

251 We further examined antibody response following DENV infection (Table S1). The results of
252 three samples each from the pDENV panel and sDENV panel were shown in Figures 1(F) and
253 1(H), respectively. Anti-E antibodies cross-reactive to all six flaviviruses, anti-NS1 antibodies to
254 one to three DENV serotypes with cross-reactivity to ZIKV or YFV, and anti-prM antibodies to
255 DENV without cross-reactivity to ZIKV, WNV or YFV were found in both panels, including
256 samples collected more than 29 years after infection (Figures 1(F) and 1(H)). A similar pattern of
257 viral protein recognition was observed in other samples of the pDENV and sDENV panels (Table
258 S2), except that the sDENV panel had a higher rate of cross-reactivity to ZIKV NS1 protein
259 compared with the pDENV panel (26.0% vs. 0%, two-tailed Fisher's exact test, $P=0.007$). As a
260 comparison, WNV samples had anti-E antibodies cross-reactive to all six flaviviruses tested, anti-
261 NS1 antibodies recognizing WNV and cross-reactive to DENV, ZIKV or YFV, and anti-prM
262 antibodies recognizing WNV only (Figure 1(G), Table S2). We next examined two samples each
263 from the pZIKV and DENV+ZIKV panels. Anti-E antibodies cross-reactive to all six flaviviruses
264 tested and anti-NS1 antibodies to ZIKV with cross-reactivity to DENV (one to three serotypes)
265 and YFV were observed in both panels. In contrast, anti-prM antibodies were found to recognize
266 ZIKV only in the pZIKV panel and recognize both ZIKV and DENV in the DENV+ZIKV panel,
267 as verified by long exposure (Figures 1(I) and 1(J), and data not shown). A similar trend was

268 observed in other samples of the pZIKV and DENV+ZIKV panels (Table S2). Table 1
269 summarizes different viral protein bands recognized in 189 samples from the seven panels.

270 Table 2 summarizes the sensitivity and specificity of antibodies recognizing different NS1 or
271 prM proteins to discriminate infection with DENV, ZIKV and WNV as well as vaccination with
272 YF-17D. The overall sensitivity of anti-NS1 antibodies ranged from 50% to 100%, and the
273 specificity 51.2% to 99.4%. In contrast, the overall sensitivity/specificity of anti-prM antibodies
274 was higher (91.7/96.4%, 91.7/99.2%, 88.9/98.3%, and 91.3/92.5% for DENV, ZIKV, WNV, and
275 YF-17D infection/vaccination, respectively), suggesting that anti-prM antibodies is a
276 serocomplex-specific marker for the four flavivirus serocomplexes tested.

277 ***Serosurveillance by testing samples from endemic countries***

278 To further examine whether or not this assay can be used for serosurveillance in countries where
279 multiple flaviviruses are endemic and sympatric, we first tested 50 samples from a fever
280 surveillance program in the Philippines between 2018 and 2019. Most samples had anti-E
281 antibodies cross-reactive to all six flaviviruses, anti-NS1 antibodies to one to three DENV
282 serotypes and/or ZIKV, and anti-prM antibodies to one to three DENV serotypes only, suggesting
283 previous DENV infection (Figure 2(A)). Other samples did not have anti-E, anti-NS1 or anti-prM
284 antibodies to DENV, ZIKV, WNV or YFV, suggesting that they were seronegative to these
285 flaviviruses (Figure 2(E)). Three samples had anti-E antibodies cross-reactive to all six
286 flaviviruses, anti-NS1 antibodies to one to three DENV serotypes and YFV or ZIKV, and anti-
287 prM antibodies to one to three DENV serotypes and YFV without cross-reactivity to ZIKV or
288 WNV, suggesting previous DENV and YFV infections/vaccination (Figure 2(B)). Four samples
289 had anti-E antibodies cross-reactive to all six flaviviruses, anti-NS1 antibodies to one to three
290 DENV serotypes and ZIKV or YFV, and anti-prM antibodies to one to three DENV serotypes and

291 ZIKV without cross-reactivity to WNV or YFV, suggesting previous DENV and ZIKV infections
292 (Figure 2(D)), whereas one sample had anti-E antibodies to ZIKV with faint cross-reactivity to
293 DENV2, anti-NS1 antibodies to ZIKV with faint cross-reactivity to DENV4, and anti-prM
294 antibodies to ZIKV only, suggesting pZIKV infection (Figure 2(C)).

295 The pattern of E and prM proteins recognized in Western blot analysis and the number/
296 percentage of positive and total samples from the Philippines are summarized in Figures 2(F) and
297 2(G). Of the 50 participants, 28 (56%) had previous DENV infection, 4 (8%) previous DENV and
298 ZIKV infections, 1 (2%) previous ZIKV infection, 3 (6%) previous DENV and YFV
299 infections/vaccination, and 14 (28%) negatives to the four flaviviruses tested; altogether 35 (70%)
300 had previous DENV infection. We further tested with a previously reported IgG ELISA based on
301 DENV FL-mutated VLP, and found 35 (70%) were positive and 15 (30%) negative (Figure 2(H));
302 this is consistent with the results of Western blot analysis. Comparing the Western blot analysis
303 and DENV FL-VLP IgG ELISA, which had a sensitivity/specificity of 100.0%/93.3%, the
304 positive, negative and overall agreements were all 1.0 with a kappa assessment of 1.0 (Figure
305 2(I)).

306 We next tested 48 samples from suspected Zika cases collected in Salvador, Brazil during the
307 early phase of the ZIKV outbreak between 2015 and 2016. Anti-E antibodies cross-reactive to all
308 six flaviviruses and anti-NS1 antibodies recognizing one to three DENV serotypes and/or ZIKV
309 or YFV were found in all samples tested. Based on the recognition of anti-prM antibodies, we
310 found four patterns. Some samples recognized DENV prM protein of one to three serotypes
311 without cross-reactivity to ZIKV, YFV or WNV, suggesting previous DENV infection (Figure
312 3(A)), whereas others recognized DENV (one to three serotypes) and ZIKV or YFV prM proteins,
313 suggesting previous DENV and ZIKV infections (Figure 3(B)) or DENV and YFV

314 infections/vaccination (Figure 3(C)), respectively. Interestingly, some samples recognized DENV
315 (one to three serotypes), ZIKV and YFV prM proteins, suggesting previous DENV, ZIKV and
316 YFV infections/vaccination (Figure 3(D)).

317 The pattern of E and prM proteins recognized in Western blot analysis and the
318 number/percentage of positive and total samples from Brazil are summarized in Figures 3(E) and
319 3(F). Of the 48 participants, 11 (22.9%) had previous DENV infection, 8 (16.7%) previous DENV
320 and ZIKV infections, 12 (25%) previous DENV and YFV infections/vaccination, and 17 (35.4%)
321 previous DENV, ZIKV and YFV infections/vaccination. Taken together, all participants (100%)
322 had previous DENV infection, 52.1% (25/48) previous ZIKV infection, and 60.4% (29/48)
323 previous YFV infection or vaccination.

324 **Discussion**

325 In this study, we employed antigens of six flaviviruses from four serocomplexes in Western blot
326 analysis to test six panels of samples with well-documented flavivirus infections or vaccination
327 and found that anti-prM antibodies is a specific marker for four flavivirus serocomplexes with an
328 overall sensitivity/specificity of 91.7%/96.4%, 91.7%/99.2%, 88.9%/98.3%, and 91.3%/92.5%,
329 for DENV, ZIKV, WNV, and YFV infections/vaccination, respectively. These findings have
330 implications for serodiagnosis and serosurveillance to further our understanding of the
331 epidemiology, transmission and immunopathogenesis in regions where multiple flaviviruses co-
332 circulate.

333 In agreement with previous reports of cross-reactivities of flavivirus E proteins [24-27], anti-
334 E antibodies were found to cross-react to all six flaviviruses (DENV1, 2 and 4, WNV, ZIKV and
335 YFV) tested in our control panels including pDENV, sDENV, pZIKV, DENV+ZIKV, WNV and
336 YF-17D panels, except that two NHPs and five participants receiving YF-17D vaccine
337 recognized YFV E protein only probably due to generally weak antibody response to live-
338 attenuated vaccine or sampling time ≤ 2 months or $> 3-5$ years after vaccination (Table S2).
339 Interestingly, anti-YFV prM antibodies were found in the majority (21/23) of YFV samples
340 tested but only in few from other control panels with an overall sensitivity/specificity of
341 91.3%/92.5% (Tables 1 and 2). Consistent with our previous report, anti-prM antibodies can
342 discriminate DENV, ZIKV and WNV infections (36). Notably, anti-prM antibodies to one to
343 three DENV serotype were detected in 22/25 of the DENV+ZIKV panel but in 2/23 of the
344 pZIKV panel ($P < 0.0001$, two tailed Fisher exact test, Table 1), suggesting that anti-DENV prM
345 antibodies can distinguish these two panels. Although the sensitivities of anti-prM antibodies,
346 ranging from 88,9% (WNV) to 91.3%–91.7% (DENV, ZIKV and YFV) were moderate, the

347 specificities were high (92.5%-99.2%), which was most interesting given that low specificity has
348 been a concern for many serological tests for flaviviruses.

349 The overall sensitivity/specificity of anti-NS1 antibodies for DENV, ZIKV, WNV, and YFV
350 infections/vaccination were 93.8/51.2%, 100/86.4%, 50.0/99.4%, and 95.7/70.8%, respectively,
351 suggesting that anti-NS1 antibody is not a specific marker for the four flavivirus serocomplexes
352 tested in our assay. Compared with ELISA, our previous study reported that detection of anti-
353 NS1 antibodies in Western blot analysis was less specific, probably due to the presence of cross-
354 reactive anti-NS1 antibodies that recognized linear epitopes in detergent-treated NS1 monomers
355 in Western blot analysis but not NS1 hexamers in solution such as in ELISA [36]. Within the
356 DENV serocomplex, we found that the sDENV panel had higher rates of detecting anti-prM and
357 anti-NS1 antibodies compared with the pDENV panel (98.0% vs. 81.0% and 98.0% vs. 76.2%,
358 respectively, $P=0.02$ and $P=0.008$, Fisher exact test, Table 1). Nonetheless, the difference was
359 insufficient to distinguish these two panels [24,36]. Of note, protein bands corresponding DENV
360 or YFV NS1 protein were recognized by some DENV-naive samples, however, none of the six
361 flavivirus E proteins tested was recognized by these samples (Table 1), suggesting non-specific
362 binding to proteins present in these cell lysates.

363 The ZIKV outbreak in the Americas has drawn renewed interest in the epidemiology and
364 transmission of ZIKV in other parts of the world (15). Several lines of evidence including
365 documented Zika cases among travelers from Southeast Asia, retrospective analysis of archived
366 samples, and enhanced surveillance suggested that ZIKV has been circulating at a low but
367 sustained level in several countries in Southeast Asia including the Philippines [46-52]. Consistent
368 with these reports, we found approximately 10% of the participants from the Philippines had
369 previous ZIKV or ZIKV and DENV infections [51,52]. The DENV detection rate of 70% among

370 the participants (aged 2–56 years) was generally in agreement with the seroprevalence rate
371 estimated previously [53]. When testing with 48 samples of suspected Zika cases collected
372 between November 2015 and June 2016 in Salvador, we found that all participants (100%) had
373 previous DENV infection and 52.1% (25/48) had previous DENV and ZIKV infections, which
374 was generally in agreement with previous reports of ZIKV seroprevalence during the early phase
375 of ZIKV outbreak in the Northeastern Brazil [54,55]. It is worth noting that the recent YFV
376 outbreak in the Southeastern Brazil started in November 2016, when deaths of NHPs due to YFV
377 infection was reported, followed by human cases since December 2016 with a total of 2237 cases
378 as of June 2019 [10,56,57]; thus, detection of anti-YFV prM antibodies in our participants was
379 unlikely due to the recent YFV outbreak. Our findings that 60.4% (29/48) of participants (aged
380 15–63 years) had anti-YFV prM antibodies was consistent with the estimated coverage rate of YF
381 vaccination in Brazil (30–70% for individuals aged 15–70 years) and suggested they had previous
382 YF-17D vaccination [58]. Nonetheless, the possibility of exposure during previous YFV
383 outbreaks (2000-2001 and 2008-2009) in the Southeastern and Northeastern states of Brazil
384 cannot be completely ruled out [10,56,57].

385 Although different neutralization tests including PRNTs, focus reduction neutralization,
386 microneutralization test, reporter viruses, and flow-based neutralization tests, have been
387 developed for flaviviruses, the requirement of labor-intensive work, trained staff, equipment and
388 appropriate biocontainment has limited their applications to reference or research laboratories.
389 Compared with PRNTs, our Western blot analysis is faster (18 h for six viral antigens vs. 5-6
390 days for PRNTs for each virus), and requires less sample volume (5 μ L vs. 128 μ L for PRNTs
391 for six antigens or viruses). Moreover, the half-membrane employed in our Western blot analysis
392 can be prepared in advance, stored in a -20°C freezer, and hybridized to serum/plasma up to four

393 months with comparable results (Figure S1), supporting potential application in regional
394 laboratories. It can also be prepared in strips for use as a simple, inexpensive and readily
395 applicable diagnostic test, as exemplified by the first-generation HIV immunoassay [59].

396 One major challenge of PRNT is that it cannot discriminate multiple flavivirus infections
397 experienced in the past, thus restricting its application for serosurveillance in flavivirus-endemic
398 regions. Despite a previous study reporting different cross-neutralization patterns observed in
399 various ZIKV and DENV infections, whether a defined neutralizing antibody titer (PRNT₅₀ titer)
400 can discriminate sDENV and DENV+ZIKV panels or it can be applied to regions where other
401 flaviviruses (YFV, WNV or JEV) are prevalent remains unclear [60]. A recent study in
402 Indonesian Archipelago, a DENV hyperendemic region, revealed multitypic neutralizing
403 antibodies to two or more DENV serotypes and suggested possible ZIKV circulation based on
404 high stringent PRNT₉₀ titers, underscoring the difficulty of using PRNT to delineate DENV and
405 ZIKV infections in hyperendemic regions [61]. Other studies used two-step neutralization tests
406 (initial screening by PRNT to ZIKV followed by PRNT to DENV1-4 and ZIKV) [48,49] or
407 combination of IgG ELISA and neutralization test (for positive or equivocal samples) to
408 investigate ZIKV or DENV seroprevalence in endemic regions [62-64]. However, the
409 interpretation of multitypic neutralizing antibody profile remains a challenge.

410 Our assay using a half membrane with six flavivirus antigens to detect IgG in Western blot
411 analysis can be combined with IgG ELISA to verify those positive or equivocal samples and
412 provide detailed information of infections/exposure of four flavivirus serocomplexes in the past.
413 Given the high specificities of anti-prM antibodies (92.5%-99.2%) in our assay, combination of
414 our assay with other serological tests is unlikely to reduce the overall specificity. Our assay has
415 several potential applications, such as determining flavivirus immune background of participants

416 in a vaccine trial or a seroepidemiological study in endemic regions, and confirming infections
417 with the four flavivirus serocomplexes during surveillance. Our assay can also be employed in
418 retrospective studies of pregnant women with CZS or normal babies to investigate the influence
419 of different ZIKV, DENV, YFV, and/or WNV immune status on pregnancy outcomes. These
420 together would improve our understanding of the epidemiology, immunopathogenesis and
421 complications of ZIKV and DENV in flavivirus-endemic regions.

422 There were several limitations of this study. First, the sample size in each panel of well-
423 documented flavivirus infections or YF-17D vaccination was relatively small; future studies with
424 larger sample size are warranted to validate these observations. Second, although samples were
425 collected from four months to 31 years after pDENV or sDENV infection and from two months
426 to five years after YF-17D vaccination, samples with longer duration following other flavivirus
427 infections such as ZIKV, DENV+ZIKV and WNV are needed to verify these observations.
428 Third, anti-YFV prM antibodies cannot distinguish YFV natural infection and vaccination with
429 YF-17D, a live-attenuated vaccine. Similarly, anti-DENV prM antibodies cannot discriminate
430 DENV natural infection and vaccinees who received live-attenuated DENV vaccines. Given the
431 availability of other flavivirus vaccines including JEV and tick-borne encephalitis virus vaccines
432 and several ongoing vaccines trials in endemic regions, serological tests that can distinguish
433 flavivirus natural infection and vaccination remain to be exploited in future studies [65,66].

434 **Acknowledgments**

435 We thank Drs. E. Harris at the University of California Berkeley and A. Balmaseda at the
436 Ministry of Health, Managua, Nicaragua for providing samples from Nicaragua, S. L. Stramer at
437 the American Red Cross at Gaithersburg, Maryland for providing samples from blood donors,
438 GJ. Chang at the Center for Disease Control and Prevention at Fort Collins for providing the
439 plasmid expressing YF-17D prM/E proteins, Colorado, and S. Verma at the John A. Burns
440 School of Medicine, University of Hawaii at Manoa for providing WNV-infected cell lysates.

441

442 **Disclosure Statement**

443 No potential conflict of interest was reported by the authors.

444

445 **Funding**

446 This work was supported by grants R01AI149502 (WKW) from the National Institute of Allergy
447 and Infectious Diseases, National Institutes of Health (NIH); P20GM130448 (YSH) from the
448 National Institute of General Medical Sciences, NIH; MedRes-2022-0000 0789 (WKW) from the
449 Hawaii Community Foundation; Grant (AKS, MJ) from the Philippine Council for Health
450 Research and Development; MOHW109-TDU-B-212-114006 (JJT) and MOHW110-TDU-B-
451 212-124006 (JJT) from the Ministry of Health and Welfare, Taiwan; and NHRI-110A1-MRCO-
452 03212101 (JJT) from the National Health Research Institute, Taiwan; Grant 404193/2019-6
453 (EMN) from the Brazilian National Council for Scientific and Technological Development
454 (CNPq). The funders had no role in study design, data collection and analysis, decision to
455 publish, or preparation of the manuscript. The content is solely the responsibility of the authors
456 and does not represent the official views of the NIH.

457

458 **Author contributions**

459 GHC, YCD and WKW contributed to study design. GHC, YCD and SZH conducted the
460 experiments. GHC, YCD and WKW performed the data analysis. GHC, YCD and WKW had
461 access to underlying data. JJT, AKS, MJ, CP, CB, EMN, PJK, DRDS, DLV, SH, YSH and
462 WKW contributed to reagent or sample collection and funding acquisition. GHC, YCD and
463 WKW contributed to manuscript writing. All authors contributed to the article and approved the
464 submitted version.

465

466 **Supplemental Materials**

467 Table S1 and S2

468 Figure S1

469 **References**

- 470 1. Pierson TC, Diamond MS. 2013. Flaviviruses. Knipe DM, Howley PM, eds. Fields virology,
471 6th ed, Philadelphia: Lippincott William & Wilkins. pp 747-794.
- 472 2. Guzman MG, Harris E. Dengue. Lancet. 2015;385:453-465.
- 473 3. Bhatt S, Gething PW, Brady OJ, et al. The global distribution and burden of dengue. Nature.
474 2013;496:504-507.
- 475 4. World Health Organization. Dengue and severe dengue. [https://www.who.int/news-](https://www.who.int/news-room/fact-sheets/detail/dengue-and-severe-dengue)
476 [room/fact-sheets/detail/dengue-and-severe-dengue](https://www.who.int/news-room/fact-sheets/detail/dengue-and-severe-dengue)
- 477 5. Halstead SB, Dans LF. Dengue infection and advances in dengue vaccines for children.
478 Lancet Child Adolesc Health. 2019;3:734-741.
- 479 6. WHO. Dengue vaccine: WHO position paper - September 2018. Weekly Epidemiological
480 Record. 2018;93:457-476.
- 481 7. Sridhar S, Luedtke A, Langevin E, et al. Effect of dengue serostatus on dengue vaccine
482 safety and efficacy. N Engl J Med. 2018;379:327-340.
- 483 8. Wilder-Smith A, Smith PG, Luo R, et al. Pre-vaccination screening strategies for the use of
484 the CYD-TDV dengue vaccine: A meeting report. Vaccine. 2019;37:5137-5146.
- 485 9. Chen LH, Wilson ME. Yellow fever control: current epidemiology and vaccination
486 strategies. Trop Dis Travel Med Vaccines. 2020;6:1.
- 487 10. de Oliveira Figueiredo P, Stoffella-Dutra AG, Barbosa Costa G, et al. Re-emergence of
488 yellow fever in Brazil during 2016-2019: challenges, lessons learned, and perspectives.
489 Viruses. 2020;12:1233.
- 490 11. Girard M, Nelson CB, Picot V, et al. Arboviruses: A global public health threat. Vaccine.
491 2020;38:3989-3994.
- 492 12. Jani C, Kakoullis L, Abdallah N, et al. West Nile virus: another emerging arboviral risk for

493 travelers? *Curr Infect Dis Rep.* 2022;24:117-128.

494 13. Lessler J, Chaisson LH, Kucirka LM, et al. Assessing the global threat from Zika virus.
495 *Science.* 2016;353:aaf8160.

496 14. PAHO, Regional Zika epidemiological update (Americas) - 25 August 2017 [accessed Dec.
497 1, 2020]. available from:
498 [http://www.paho.org/hq/index.php?option=com_content&view=article&id=11599&Itemid](http://www.paho.org/hq/index.php?option=com_content&view=article&id=11599&Itemid=41691&lang=en)
499 [=41691&lang=en](http://www.paho.org/hq/index.php?option=com_content&view=article&id=11599&Itemid=41691&lang=en)

500 15. Musso D, Ko AI, Baud D. Zika virus infection - after the pandemic. *N Engl J Med.*
501 2019;381:1444-1457.

502 16. Anderson KB, Gibbons RV, Thomas SJ, et al. Preexisting Japanese encephalitis virus
503 neutralizing antibodies and increased symptomatic dengue illness in a school-based cohort
504 in Thailand. *PLoS Negl Trop Dis.* 2011;5:e1311.

505 17. Rodriguez-Barraquer I, Costa F, Nascimento EJM, et al. Impact of preexisting dengue
506 immunity on Zika virus emergence in a dengue endemic region. *Science.* 2019;363:607-
507 610.

508 18. Gordon A, Gresh L, Ojeda S, et al. Prior dengue virus infection and risk of Zika: A pediatric
509 cohort in Nicaragua. *PLoS Med.* 2019;16:e1002726.

510 19. Katzelnick LC, Narvaez C, Arguello S, et al. Zika virus infection enhances future risk of
511 severe dengue disease. *Science.* 2020;369:1123-8.

512 20. Tsai WY, Lin HE, Wang WK. Complexity of human antibody response to dengue virus:
513 implication for vaccine development. *Front Microbiol.* 2017;8:1372.

514 21. Martin DA, Muth DA, Brown T, et al. 2000. Standardization of immunoglobulin M capture
515 enzyme-linked immunosorbent assays for routine diagnosis of arboviral infections. *J Clin*

516 Microbiol. 2000;38:1823-1826.

517 22. Johnson AJ, Martin DA, Karabatsos N, et al. Detection of anti-arboviral immunoglobulin G
518 by using a monoclonal antibody-based capture enzyme-linked immunosorbent assay. J Clin
519 Microbiol. 2000;38:1827-1831.

520 23. Guidance for U.S. Laboratories testing for Zika virus infection. From CDC's website:
521 <http://www.cdc.gov/zika/laboratories/lab-guidance.html>.

522 24. Lai CY, Tsai WY, Lin SR, et al. Antibodies to envelope glycoprotein of dengue virus during
523 the natural course of infection are predominantly cross-reactive and recognize epitopes
524 containing highly conserved residues at the fusion loop of domain II. J Virol. 2008;82:6631-
525 6643.

526 25. Lanciotti RS, Kosoy OL, Laven JJ, et al. Genetic and serologic properties of Zika virus
527 associated with an epidemic, Yap State, Micronesia, 2007. Emerg Infect Dis. 2008;14:1232-
528 1239.

529 26. Johnson BW, Kosoy O, Martin DA, et al. West Nile virus infection and serologic response
530 among persons previously vaccinated against yellow fever and Japanese encephalitis
531 viruses. Vector Borne Zoonotic Dis. 2005;5:137-145.

532 27. Felix AC, Souza NCS, Figueiredo WM, et al. Cross reactivity of commercial anti-dengue
533 immunoassays in patients with acute Zika virus infection. J Med Virol. 2017;89:1477-1479.

534 28. Steinhagen K, Probst C, Radzimski C, et al. Serodiagnosis of Zika virus (ZIKV) infections
535 by a novel NS1-based ELISA devoid of cross-reactivity with dengue virus antibodies: a
536 multicohort study of assay performance, 2015 to 2016. Euro Surveill. 2016;21:30426.

537 29. Safronetz D, Sloan A, Stein DR, et al. Evaluation of 5 commercially available Zika virus
538 immunoassays. Emerg Infect Dis. 2017;23:1577-1580.

539 30. Balmaseda A, Zambrana JV, Collado D, et al. Comparison of four serological methods and
540 two reverse transcription-PCR assays for diagnosis and surveillance of Zika virus infection.
541 J Clin Microbiol. 2018;56:e01785-17.

542 31. Tsai WY, Youn HH, Brites C, et al. Distinguishing secondary dengue virus infection from
543 Zika virus infection with previous dengue by combination of three simple serological tests.
544 Clin Infect Dis. 2017;65:1829-1836.

545 32. Tyson J, Tsai WY, Tsai JJ, et al. A high-throughput and multiplex microsphere
546 immunoassay based on non-structural protein 1 can discriminate three flavivirus infections.
547 PLoS Negl Trop Dis. 2019; 13:e0007649.

548 33. Innis BL. 1997. Antibody responses to dengue virus infection. In Gubler DJ, Kuno G eds:
549 Dengue and dengue hemorrhagic fever. Cambridge, MA: CAB International, pp. 221-244.

550 34. Halstead SB. Neutralization and antibody-dependent enhancement of dengue viruses. Adv.
551 Virus Res. 2003;60:421-467.

552 35. Alvarez M, Rodriguez-Roche R, Bernardo L, et al. Dengue hemorrhagic Fever caused by
553 sequential dengue 1-3 virus infections over a long time interval: Havana epidemic, 2001-
554 2002. Am J Trop Med Hyg. 2006;75:1113-1117.

555 36. Hsieh SC, Tsai WY, Tsai JJ, et al. Identification of anti-premembrane antibody as a
556 serocomplex-specific marker to discriminate Zika, dengue, and West Nile virus infections. J
557 Virol. 2021;95:e0061921.

558 37. Kuan G, Gordon A, Avilés W, et al. The Nicaraguan pediatric dengue cohort study: study
559 design, methods, use of information technology, and extension to other infectious diseases.
560 Am J Epidemiol. 2009;170:120-129.

561 38. NarvaezF, Gutierrez G, Perez MA, et al. Evaluation of the Traditional and revised WHO

562 classifications of dengue disease severity. *PLoS Negl Trop Dis.* 2011;5:e1397.

563 39. Herrera BB, Tsai WY, Brites C, et al. T cell responses to nonstructural protein 3 distinguish
564 infections by dengue and Zika viruses. *mBio.* 2018;9: e00755-18.

565 40. Tyson J, Tsai WY, Tsai JJ, et al. Combination of non-structural protein 1-based enzyme-
566 linked immunosorbent assays can detect and distinguish various dengue virus and Zika
567 virus infections. *J Clin Microbiol.* 2019;57:e01464-18.

568 41. Tsai JJ, Liu CK, Tsai WY, et al. Seroprevalence of dengue in two districts of Kaohsiung city
569 after the largest dengue outbreak in Taiwan since world war II. *PLoS Negl Trop Dis.*
570 2018;12: e0006879

571 42. Tsai WY, Chen HL, Tsai JJ, et al. Potent neutralizing human monoclonal antibodies
572 preferentially target mature dengue virus particles: implication for novel strategy of dengue
573 vaccine. *J Virol.* 2018;92:e00556-18.

574 43. Dai YC, Sy AK, Jiz M, et al. Identification of prior dengue-naïve Dengvaxia recipients with
575 an increased risk for symptomatic dengue during fever surveillance in the Philippines. *Front*
576 *Immunol* 2023;14:1202055.

577 44. Tsai WY, Driesse K, Tsai JJ, et al. Enzyme-linked immunosorbent assays using virus-like
578 particles containing mutations of conserved residues on envelop protein can distinguish three
579 flavivirus infections. *Emerg Microbe Infect.* 2020;9:1722-1732.

580 45. Frey A, Di Canzio J, Zurakowski D. A statistically defined endpoint titer determination
581 method for immunoassays. *J. Immunol. Methods.* 1998;221:35–41.

582 46. Duong V, Dussart P, Buchy P. Zika virus in Asia. *Int J Infect Dis.* 2017;54:121-128.

583 47. Sasmono RT, Dhenni R, Yohan B, et al. Zika virus seropositivity in 1-4-year-old children,
584 Indonesia, 2014. *Emerg Infect Dis.* 2018;24:1740-1743.

585 48. Sasmono RT, Johar E, Yohan B, et al. Spatiotemporal heterogeneity
586 of Zika virus transmission in Indonesia: serosurveillance data from a pediatric population.
587 Am J Trop Med Hyg. 2021;104:2220-2223.

588 49. Pastorino B, Sengvilaipaseuth O, Chanthongthip A, et al. Low Zika virus seroprevalence in
589 Vientiane, Laos, 2003-2015. Am J Trop Med Hyg. 2019;100:639-642.

590 50. Ruchusatsawat K, Wongjaroen P, Posanacharoen A, et al. Long-term circulation
591 of Zika virus in Thailand: an observational study. Lancet Infect Dis. 2019;19:439-446.

592 51. Biggs JR, Sy AK, Brady OJ, et al. Serological evidence of widespread Zika transmission
593 across the Philippines. Viruses. 2021;13:1441.

594 52. Lonogan K, de Guzman A, Delos Reyes VC, et al. The enhanced Zika surveillance in the
595 Philippines, November 14, 2016–February 28, 2017. Int J Infect Dis. 2020, 101;232–233.

596 53. L'Azou M, Moureau A, Sarti E, et al. Symptomatic Dengue in Children in 10 Asian and
597 Latin American Countries. N Engl J Med. 2016;374:1155-1166.

598 54. Netto EM, Moreira-Soto A, Pedroso C, et al. High Zika virus seroprevalence in Salvador,
599 Northeastern Brazil limits the potential for further outbreaks. MBio. 2017;8 e01390-17.

600 55. Alves LV, Leal CA, Alves JGB. Zika virus seroprevalence in women who gave birth
601 during Zika virus outbreak in Brazil - a prospective observational study. Heliyon.
602 2020;6:e04817.

603 56. Rezende IM, Sacchetto L, Munhoz de Mello É, et al. Persistence of yellow fever virus
604 outside the Amazon Basin, causing epidemics in Southeast Brazil, from 2016 to 2018. PLoS
605 Negl Trop Dis. 2018;12:e0006538.

606 57. Dexheimer Paploski IA, Souza RL, Tauro LB, et al. Epizootic outbreak of yellow fever virus
607 and risk for human disease in Salvador, Brazil. Ann Intern Med. 2018;168:301-302.

608 58. Shearer FM, Moyes CL, Pigott DM, et al. Global yellow fever vaccination coverage from
609 1970 to 2016: an adjusted retrospective analysis. *Lancet Infect Dis.* 2017;17:1209-17.

610 59. Centers for Disease Control and Prevention and Association of Public Health Laboratories.
611 Laboratory Testing for the Diagnosis of HIV Infection: Updated Recommendations. 2014.
612 <http://stacks.cdc.gov/view/cdc/23447>.

613 60. Montoya M, Collins M, Dejnirattisai W, et al. Longitudinal analysis of antibody cross-
614 neutralization following Zika virus and dengue virus infection in Asia and the Americas. *J*
615 *Infect Dis.* 2018;218:536-545.

616 61. Harapan H, Panta K, Michie A, et al. Hyperendemic dengue and possible Zika circulation in
617 the westernmost region of the Indonesian Archipelago. *Viruses.* 2022;14:219.

618 62. Nurtop E, Villarroel PMS, Pastorino B, et al. Combination of ELISA screening and
619 seroneutralisation tests to expedite Zika virus seroprevalence studies. *Virology.* 2018;15:192.

620 63. Saba Villarroel PM, Nurtop E, Pastorino B, et al. Zika virus epidemiology in Bolivia: A
621 seroprevalence study in volunteer blood donors. *PLoS Negl Trop Dis.* 2018;12:e0006239.

622 64. Lopez AL, Adams C, Ylade M, et al. Determining dengue virus serostatus by indirect IgG
623 ELISA compared with focus reduction neutralisation test in children in Cebu, Philippines: a
624 prospective population-based study. *Lancet Glob Health.* 2021;9:e44-e51.

625 65. Simmons G, Stone M, Busch MP. 2018. Arbovirus diagnostics: from bad to worse due to
626 expanding dengue virus vaccination and Zika virus epidemics. *Clin Infect Dis.* 2018;
627 66:1181-13.

628 66. Munoz-Jordan JL. Diagnosis of Zika virus infections: challenges and opportunities. *J Infect*
629 *Dis.* 2017;216:S951-S956.

630 **Figure Legends**

631 **Figure 1.** Antibody response to six flavivirus antigens following YF-17D vaccination or DENV,
632 ZIKV or WNV infection. Lysates derived from mock-, DENV1-, DENV2-, DENV4-, WNV-,
633 ZIKV-, and YFV (17D strain)-infected Vero cells were subjected to SDS-12% polyacrylamide
634 gel electrophoresis under non-reducing condition and Western blot analysis probed with different
635 serum/plasma samples or anti-E mouse mAb FL0232 (C). Results of YF-17D vaccinees (A) and
636 NHPs receiving YF-17D vaccine (D), DENV-naïve participant (E), and participants with pDENV
637 (F), WNV (G), sDENV (H), pZIKV (I), and DENV+ZIKV (D+ZK) (J) infections. Lysates
638 derived from 293T cells transfected with YF-17D prM/E plasmid were subjected to Western blot
639 analysis and probed with a DENV- and YFV-immune serum, short (left) and long (right)
640 exposure (B). The sampling time post-symptom onset, vaccination or TMA test was indicated
641 after sample ID. pDENV, primary DENV infection; sDENV, secondary DENV infection;
642 pZIKV, primary ZIKV infection. The positions of E, NS1 and prM protein bands are indicated.
643 The size of molecular weight markers is shown in kDa. Mo: mock, D1: DENV1, D2: DENV2,
644 D4: DENV4, WN: WNV, ZK: ZIKV, and YF: YF-17D.


645

646 **Figure 2.** Antibody response to six flavivirus antigens in samples from a fever surveillance
647 program in the Philippines. (A-E) Results of participants with previous DENV infection (A),
648 previous DENV and YFV infections/vaccination (D+YF) (B), pZIKV infection (C), previous
649 DENV and ZIKV infections (D+ZK) (D), and seronegative to DENV, ZIKV, YFV and WNV
650 (Neg) (E). The positions of E, NS1 and prM protein bands are indicated. The size of molecular
651 weight markers is shown in kDa. Mo: mock, D1: DENV1, D2: DENV2, D4: DENV4, WN:
652 WNV, ZK: ZIKV, and YF: YF-17D. (F,G) The pattern of E and prM proteins recognized and the


653 number/percentage of positive and total samples based on Western blot analysis (F) and a graphic
654 summary (G). (H,I) Results of DENV FL-VLP IgG ELISA (H) and comparison with that of anti-
655 DENV prM reactivity in Western blot analysis (I). rOD: the relative OD. The two-tailed Mann-
656 Whitney test was performed in panel H.

657
658 **Figure 3.** Antibody response to six flavivirus antigens in samples from suspected ZIKV cases
659 during the ZIKV outbreak in Brazil. (A-D) Results of participants with previous DENV infection
660 (A), previous DENV and ZIKV infections (D+ZK) (B) previous DENV and YFV
661 infections/vaccination (D+YF) (C), and previous DENV, ZIKV and YFV infections/vaccination
662 (D+ZK+YF) (D). The positions of E, NS1 and prM protein bands are indicated. The size of
663 molecular weight markers is shown in kDa. Mo: mock, D1: DENV1, D2: DENV2, D4: DENV4,
664 WN: WNV, ZK: ZIKV, and YF: YF-17D. (E,F) The pattern of E and prM proteins recognized
665 and the number/percentage of positive and total samples based on Western blot analysis (E) and a
666 graphic summary (F).

F1





F2



F

| E and prM proteins recognized in WB analysis | No. of positive /total (%) | Interpretation |
|--|----------------------------|----------------|
| D1, D2 or D4 prM+, all E+ | 28/50 (56%) | DENV |
| D1, D2 or D4 prM+, ZIKV prM+, all E+ | 4/50 (8%) | DENV+ZIKV |
| D1, D2 or D4 prM-, ZIKV prM+, Z E+ | 1/50 (2%) | pZIKV |
| D1, D2 or D4 prM+, YFV prM+, all E+ | 3/50 (6%) | DENV+YFV |
| D1, D2 or D4 prM-, ZIKV prM-, YFV prM-, all E- | 14/50 (28%) | negative |




I

| | | DENV FL-VLP IgG ELISA | | |
|---------------------|-------|-----------------------|-----|-------|
| | | pos | neg | total |
| anti-DENV prM in WB | pos | 35 | 0 | 35 |
| | neg | 0 | 15 | 15 |
| | total | 35 | 15 | 50 |

positive agreement=1.0 overall agreement=1.0
negative agreement=1.0 kappa assessment=1.0

F3



E

| E and prM proteins recognized in WB analysis | No. of positive /total (%) | Interpretation |
|--|----------------------------|----------------|
| D1, D2 or D4 prM+, all E+ | 11/48 (22.9%) | DENV |
| D1, D2 or D4 prM+, ZIKV prM+, all E+ | 8/48 (16.7%) | DENV+ZIKV |
| D1, D2 or D4 prM+, YFV prM+, all E+ | 12/48 (25.0%) | DENV+YFV |
| D1, D2 or D4 prM+, ZIKV prM+, YFV prM+, all E+ | 17/48 (35.4%) | DENV+ZIKV+YFV |
| D1, D2 or D4 prM-, ZIKV prM-, YFV prM-, all E- | 0/48 (0%) | negative |




Table 1. Summary of viral proteins recognized by different panels^a in Western blot analysis

| Protein bands recognized ^{c,d} | No. of positive/total samples (%) in different serum/plasma panels | | | | | | |
|---|--|--------------------------------|--------------------------------|-------------------------------|--------------------------------|--------------------------------|--------------------------------|
| | DENV-naive | pDENV | sDENV | pZIKV | DENV+ZIKV | WNV ^b | YF-17D |
| D1, D2 or D4 NS1 | 6/29 (20.7%) | 16/21 (76.2%) | 49/50 (98.0%) | 20/23 (87.9%) | 25/25 (100%) | 14/18 (77.8%) | 1/14 ^g (7.1%) |
| ZIKV NS1 | 0/29 (0%) | 0/21 (0%) | 13/50 (26.0%) | 23/23 (100%) | 25/25 (100%) | 5/18 (27.8%) | 0/14 ^g (0%) |
| WNV NS1 | 0/29 (0%) | 0/21 (0%) | 0/50 (0%) | 0/23 (0%) | 1/25 (4.0%) | 9/18 (50.0%) | 0/23 (0%) |
| YFV NS1 | 7/29 (24.1%) | 5/17 ^f (29.4%) | 6/29 ^f (20.7%) | 3/18 ^f (16.7%) | 10/13 ^f (76.9%) | NA ^e | 22/23 (95.7%) |
| D1, D2 or D4 prM | 0/29 (0%) | 17/21 (81.0%) | 49/50 (98.0%) | 2/23 (8.7%) | 22/25 (88.0%) | 0/18 (0%) | 1/14 ^g (7.1%) |
| ZIKV prM | 0/29 (0%) | 0/21 (0%) | 1/50 (2.0%) | 23/23 (100%) | 21/25 (84.0%) | 0/18 (0%) | 0/14 ^g (0%) |
| WNV prM | 0/29 (0%) | 0/21 (0%) | 0/50 (0%) | 0/23 (0%) | 3/25 (12.0%) | 16/18 (88.9%) | 0/23 (0%) |
| YFV prM | 1/29 (3.4%) | 1/17 ^f (5.9%) | 2/29 ^f (6.9%) | 2/18 ^f (11.1%) | 2/13 ^f (15.4%) | NA ^e | 21/23 (91.3%) |
| any E (D1, D2, D4, ZIKV, WNV or YFV) | 0/29 (0%) | 21/21 (100%) | 50/50 (100%) | 23/23 (100%) | 25/25 (100%) | 18/18 (100%) | 23/23 (100%) |

^apDENV, primary DENV infection; sDENV, secondary DENV infection; pZIKV, primary ZIKV infection; DENV+ZIKV, previous DENV and ZIKV infections; WNV, WNV infection; YF-17D, YF-17D vaccination.

^bIndex samples tested positive for WNV transcription-mediated amplification, IgM and IgG from blood donors at the American Red Cross [40].

^cNS1, nonstructural protein 1; prM, premembrane; D1, DENV1; D2, DENV2; D4, DENV4.

^dNo. (%) of homologous prM and NS1 proteins recognized by each panel are bolded.

^eNA, not applicable; the history of YF-17D vaccination was not available in this panel.

^fDue to the lack of history of YF-17D vaccination or infection from a subset of the pDENV (n=4), sDENV (n=21), pZIKV (n=5) and DENV+ZIKV (n=12) panels from Brazil, these samples were not included in the analysis of YFV NS1 or prM recognition.

^gDue to the lack of history of DENV or ZIKV infection from a subset of the YF-17D (n=9) panel from Brazil, these samples were not included in the analysis of DENV and ZIKV NS1 or prM recognition.

Table 2. Sensitivity and specificity of viral proteins recognized by different panels in Western blot analysis

| Viral proteins recognized ^c | Group | % Sensitivity (95% CI) ^{a,b} | % Specificity (95% CI) ^{a,b} |
|--|----------|--|--|
| D1, D2 or D4 NS1 | overall | 93.8 (88.9–96.2) | 51.2 (40.5–56.6) |
| | subgroup | pDENV:76.2, sDENV:98.0, DENV+ZIKV:100 | DENV-naive:79.3, pZIKV:87.0, WNV:22.2, YF-17D:92.9 |
| ZIKV NS1 | overall | 100 (100–100) | 86.4 (80.5–89.4) |
| | subgroup | pZIKV:100, DENV+ZIKV:100 | DENV-naive:100, pDENV:100, sDENV:74.0, WNV:72.2, YF-17D:100 |
| WNV NS1 | overall | 50.0 (26.9–61.8) | 99.4 (98.3–100) |
| | subgroup | WNV:50.0 | DENV-naive:100, pDENV:100, sDENV:100, pZIKV:100, DENV+ZIKV:96.0, YF-17D:100 |
| YFV NS1 | overall | 95.7 (87.3–99.9) | 70.8 (62.1–75.2) |
| | subgroup | YF17D:95.7 | DENV-naive:75.9, pDENV:70.6, sDENV:79.3, pZIKV:83.3, DENV+ZIKV:23.1, WNV:NA ^e |
| D1, D2 or D4 prM | overall | 91.7 (86.1–94.5)^d | 96.4 (92.5–98.5)^d |
| | subgroup | pDENV:81.0, sDENV:98.0, DENV+ZIKV:88.0 | DENV-naive:100, pZIKV:91.3, WNV:100, YF-17D:92.9 |
| ZIKV prM | overall | 91.7 (83.9–95.7)^d | 99.2 (97.8–100)^d |
| | subgroup | pZIKV:100, DENV+ZIKV:84.0 | DENV-naive:100, pDENV:100, sDENV:98.0, WNV:100, YF-17D:100 |
| WNV prM | overall | 88.9 (74.4–96.3)^d | 98.3 (96.3–99.3)^d |
| | subgroup | pWNV:88.9 | DENV-naive:100, pDENV:100, sDENV:100, pZIKV:100, DENV+ZIKV:88.0, YF-17D:100 |
| YFV prM | overall | 91.3 (79.8–97.2)^d | 92.5 (87.4–95.0)^d |
| | subgroup | YF17D:91.3 | DENV-naive:96.6, pDENV:94.1, sDENV:93.1, pZIKV:88.9, DENV+ZIKV:84.6, WNV:NA ^e |

^aCI, confidence interval. pDENV, primary DENV infection; sDENV, secondary DENV infection; pZIKV, primary ZIKV infection; DENV+ZIKV, previous DENV and ZIKV infections; WNV, WNV infection; YF-17D, YF-17D vaccination.

^bFor simplicity, the 95% CIs in the subgroup are not shown.

^cNS1, nonstructural protein 1; prM, premembrane; D1, DENV1; D2, DENV2; D4, DENV4.

^dThe sensitivity and specificity of recognizing prM protein are bolded.

^eNA, not applicable; the history of YF-17D vaccination was not available in this panel.